05:15 PM EST, 03/06/2025 (MT Newswires) -- Foghorn Therapeutics ( FHTX ) late Thursday reported a 2024 net loss of $1.58 per diluted share, compared with $2.34 a year earlier.

Analysts polled by FactSet, on average, expected $1.54.

Collaboration revenue for the 12 months ended Dec. 31 was $22.6 million, compared with $34.2 million a year earlier.

Analysts expected $29.5 million.

Foghorn shares were down 2.2% in after-hours session.